For health care professionals
Seattle Cancer Care Alliance (SCCA) is a nationally recognized treatment center that provides advanced therapies and clinical trials for cancers and other blood disorders. SCCA unites the doctors and technology from Fred Hutchinson Cancer Research Center, UW Medicine and Seattle Children's and provides a variety of resources for community doctors and other healthcare professionals.
News from our blog
SCCA is proud that our own Stephanie Lee, MD, MPH served as the 2020 president of the American Society of Hematology (ASH). Dr. Lee is a highly regarded expert in graft-versus-host disease, as well as blood and bone marrow diseases. We asked Dr. Lee about her time as president of ASH and what she sees as the direction of oncology care in the future.
For years, sarcoma treatment was formulaic: Patients would cycle through standard chemotherapies and, if those were ineffective, there were few other options. But the sarcoma landscape has changed dramatically, with a surge of innovative drugs and investigational approaches that are creating hope against sarcoma and extending survival for some patients.
In a large randomized clinical trial, researchers evaluated the immunotherapy drug avelumab for patients with advanced urothelial cancer. The findings of the trial, called the JAVELIN Bladder 100 study, are “very exciting," even "practice-changing,” said Dr. Petros Grivas, of SCCA, co-leader of this global, industry-sponsored trial.
SCCA recently launched a Thoracic Oncology Multispecialty Clinic (TOMC) to bring multidisciplinary care to patients with lung cancer and other thoracic cancers. The clinic unites top thoracic surgeons, radiation oncologists and medical oncologists to evaluate patients and design customized treatment plans.
- Seeking a breakthrough in DLBCL combination therapies with Dr. Ryan Lynch
- Understanding treatment options for standard- and high-risk CLL with Dr. Mazyar Shadman
- New data on risks and treatment for patients with cancer and COVID-19
- SCCA Offers Appleby Procedure
- SCCA is Committed to Bring World-Class Cancer Treatment to Patients in Their Own Communities
- American Society of Hematology Abstract: Effects of Tranexamic Acid Prophylaxis on Bleeding Outcomes in Hematologic Malignancy: The a-TREAT Trial
- American Society of Hematology Abstract: Third Generation CD20 Targeted CAR T-Cell Therapy (MB-106) for Treatment of Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
- American Society of Hematology Abstract: Existing Agents, Novel Agents, or Transplantation for High Risk MDS
- MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study in Subjects with Metastatic Pancreatic Ductal Adenocarcinoma
- Investigator: Andrew Coveler, MD
- In our ongoing effort to support pancreatic cancer patients, SCCA is offering a groundbreaking trial that combines immunotherapy and chemotherapy. Recent research is finding that when new immunotherapy drugs are given with chemotherapy (anti-cancer) drugs that the cancer growth can slow down or stop for longer periods of time and keep your cancer from getting bigger.
- Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies
- Investigator: Andrew J. Cowan, MD
- Phase I Study of Adoptive Immunotherapy with CD8+ and CD4+ Memory T cells Transduced to Express an HA-1-specific T cell Receptor (TCR) for Children and Adults with Recurrent Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation (HCT)
- Investigator: Elizabeth F. Krakow, MD, MSc
- Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
- Investigator: Masumi Ueda, MD
- Investigator: Masumi Ueda, MD